Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

Concomitant administration may improve vaccination rates. This analysis of a phase 1/2 randomized study included 1073 healthy ≥65-year-olds who previously received ≥3 mRNA COVID-19 vaccine doses. Participants received concomitantly administered RSVpreF and bivalent BA.4/BA.5-adapted BNT162b2 vaccine...

Full description

Saved in:
Bibliographic Details
Main Authors: Joel M. Neutel, Rahsan Erdem, Qin Jiang, Kevin Cannon, Helen Stacey, Ryan Newton, Emily Gomme, Wen Li, Federico J. Mensa, Özlem Türeci, Uğur Şahin, Kena A. Swanson, Iona Munjal, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Vaccines
Subjects:
BNT162b2
concomitant
immunogenicity
RSVpreF
QIV
noninferiority
Online Access:https://www.mdpi.com/2076-393X/13/2/158
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items